These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 34328666)

  • 1. Inhibition of IRAK1/4 enhances the antitumor effect of lenvatinib in anaplastic thyroid cancer cells.
    Kawamura Y; Saijo K; Imai H; Ishioka C
    Cancer Sci; 2021 Nov; 112(11):4711-4721. PubMed ID: 34328666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer.
    Di Desidero T; Orlandi P; Gentile D; Banchi M; Alì G; Kusmic C; Armanetti P; Cayme GJ; Menichetti L; Fontanini G; Francia G; Bocci G
    Pharmacol Res; 2020 Aug; 158():104920. PubMed ID: 32461187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.
    Ferrari SM; Bocci G; Di Desidero T; Elia G; Ruffilli I; Ragusa F; Orlandi P; Paparo SR; Patrizio A; Piaggi S; La Motta C; Ulisse S; Baldini E; Materazzi G; Miccoli P; Antonelli A; Fallahi P
    Oncol Rep; 2018 May; 39(5):2225-2234. PubMed ID: 29517103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance.
    Khan HY; Ge J; Nagasaka M; Aboukameel A; Mpilla G; Muqbil I; Szlaczky M; Chaker M; Baloglu E; Landesman Y; Mohammad RM; Azmi AS; Sukari A
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non‑invasive monitoring of paclitaxel and lenvatinib efficacy against anaplastic thyroid cancer in orthotopic SCID mouse models using small‑animal FDG‑PET/CT.
    Aoyama M; Takizawa H; Otani T; Inoue S; Kawakita N; Tsuboi M; Bando Y; Uehara H; Kondo K; Tangoku A
    Oncol Rep; 2020 Oct; 44(4):1709-1716. PubMed ID: 32945510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma.
    Dierks C; Seufert J; Aumann K; Ruf J; Klein C; Kiefer S; Rassner M; Boerries M; Zielke A; la Rosee P; Meyer PT; Kroiss M; Weißenberger C; Schumacher T; Metzger P; Weiss H; Smaxwil C; Laubner K; Duyster J; von Bubnoff N; Miething C; Thomusch O
    Thyroid; 2021 Jul; 31(7):1076-1085. PubMed ID: 33509020
    [No Abstract]   [Full Text] [Related]  

  • 7. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer.
    Iñiguez-Ariza NM; Ryder MM; Hilger CR; Bible KC
    Thyroid; 2017 Jul; 27(7):923-927. PubMed ID: 28471306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-throughput screening identified pacritinib as a promising therapeutic approach to overcome lenvatinib resistance in hepatocellular carcinoma by targeting IRAK1.
    Li C; Chen X; Wu J; Heng S; Xu Z; Gu H; Lin E; Wang J; Shan Y
    Biochem Biophys Res Commun; 2024 Nov; 734():150782. PubMed ID: 39378786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer.
    Gunda V; Gigliotti B; Ashry T; Ndishabandi D; McCarthy M; Zhou Z; Amin S; Lee KE; Stork T; Wirth L; Freeman GJ; Alessandrini A; Parangi S
    Int J Cancer; 2019 May; 144(9):2266-2278. PubMed ID: 30515783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan.
    Takahashi S; Tahara M; Ito K; Tori M; Kiyota N; Yoshida K; Sakata Y; Yoshida A
    Adv Ther; 2020 Sep; 37(9):3850-3862. PubMed ID: 32676927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis.
    Kim SY; Kim SM; Kim JW; Lee IJ; Jeon TJ; Chang H; Kim BW; Lee YS; Chang HS; Park CS
    Front Endocrinol (Lausanne); 2020; 11():599. PubMed ID: 32982983
    [No Abstract]   [Full Text] [Related]  

  • 12. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.
    Takahashi S; Kiyota N; Yamazaki T; Chayahara N; Nakano K; Inagaki L; Toda K; Enokida T; Minami H; Imamura Y; Fukuda N; Sasaki T; Suzuki T; Ikezawa H; Dutcus CE; Tahara M
    Future Oncol; 2019 Mar; 15(7):717-726. PubMed ID: 30638399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells.
    Lee YS; Kim SM; Kim BW; Chang HJ; Kim SY; Park CS; Park KC; Chang HS
    Neoplasia; 2018 Feb; 20(2):197-206. PubMed ID: 29331886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy and Safety of Lenvatinib for Unresectable Anaplastic Thyroid Cancer].
    Yamazaki H; Shimizu S; Iwasaki H; Yoshida T; Suganuma N; Yamanaka T; Kojima I; Masudo K; Toda S; Nakayama H; Masuda M
    Gan To Kagaku Ryoho; 2017 Aug; 44(8):695-697. PubMed ID: 28860443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice.
    Wang R; Yamada T; Arai S; Fukuda K; Taniguchi H; Tanimoto A; Nishiyama A; Takeuchi S; Yamashita K; Ohtsubo K; Matsui J; Onoda N; Hirata E; Taira S; Yano S
    Mol Cancer Ther; 2019 May; 18(5):947-956. PubMed ID: 30926637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited efficacy of lenvatinib in heavily pretreated anaplastic thyroid cancer: a French overview.
    Sparano C; Godbert Y; Attard M; Do Cao C; Zerdoud S; Roudaut N; Joly C; Berdelou A; Hadoux J; Lamartina L; Schlumberger M; Leboulleux S
    Endocr Relat Cancer; 2021 Jan; 28(1):15-26. PubMed ID: 33112817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer.
    Kim SY; Kim SM; Chang HJ; Kim BW; Lee YS; Park CS; Park KC; Chang HS
    BMC Cancer; 2018 Oct; 18(1):956. PubMed ID: 30286728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Anaplastic Thyroid Carcinoma.
    Osawa Y; Gozawa R; Koyama K; Nakayama T; Sagoh T; Sunaga H
    Intern Med; 2018 Apr; 57(7):1015-1019. PubMed ID: 29225265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3K/mTOR inhibition potentiates and extends palbociclib activity in anaplastic thyroid cancer.
    Wong K; Di Cristofano F; Ranieri M; De Martino D; Di Cristofano A
    Endocr Relat Cancer; 2019 Apr; 26(4):425-436. PubMed ID: 30699064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A long survival patient of anaplastic thyroid carcinoma treated with lenvatinib.
    Hamamoto T; Kono T; Taruya T; Ishino T; Ueda T; Takeno S
    Auris Nasus Larynx; 2022 Jun; 49(3):515-519. PubMed ID: 33109426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.